Emory University Hospital
- Type
- Teaching hospital
- Where
- Atlanta, GA
- Medicare CCN
- 110010
- Received
- $58,486,157 in 5,150 records, 2025 ($7,168,280 general, $51,317,876 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 357 | $7,168,280 |
| 2025 | Research payment | 4,793 | $51,317,876 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 4,793 | $51,317,876 |
| Grant | 91 | $3,781,149 |
| Royalty or License | 18 | $1,937,784 |
| Space rental or facility fees (teaching hospital only) | 94 | $457,969 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 22 | $423,140 |
| Education | 62 | $397,922 |
| Charitable Contribution | 9 | $63,461 |
| Consulting Fee | 11 | $59,350 |
| Gift | 5 | $19,700 |
| Long term medical supply or device loan | 30 | $17,815 |
| Debt forgiveness | 10 | $9,477 |
| Food and Beverage | 5 | $509 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | $704,326 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase 2 study of docetaxel, ramucirumab, and pembrolizumab for patients with metastatic or recurrent non-small cell lu | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $474,223 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | STUDY NAME#Phase II Single-Arm Study of Enfortumab Vedotin EV plus Pembrolizumab in the Treatment of Locally Advanced or | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $354,789 | Research payment | In-kind items and services | Biological, ONCOLOGY | A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $302,030 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $180,119 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $88,801 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $65,609 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $50,942 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $50,942 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $37,894 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2025 |
| 2025-12-31 | PFIZER INC. | $28,345 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $28,137 | Research payment | In-kind items and services | DOCETAXEL Drug, ONCOLOGY | A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $26,962 | Education | In-kind items and services | NA Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $26,605 | Research payment | In-kind items and services | ERVEBO Biological, VACCINE | A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire rVSV G-ZEBOV-GP fo | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $23,110 | Education | In-kind items and services | NA Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $22,865 | Education | In-kind items and services | NA Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $22,155 | Research payment | Cash or cash equivalent | Eclipse Treatment Planning System for External Beam Radiation Therapy Device, Oncology | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $21,097 | Education | In-kind items and services | IMAGE1 PILOT Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $19,981 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $19,700 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | STUDY NAME#Comparing the antibody and B cell responses induced by 1- or 2-dose 9- valent HPV 9vHPV vaccination in health | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $19,225 | Education | In-kind items and services | D3-LINK Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $18,351 | Education | In-kind items and services | IMAGE1 S CONNECT Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $14,166 | Research payment | In-kind items and services | PIFELTRO Drug, INFECTIOUS DISEASE | A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine,Lamivudine, | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $14,014 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combin | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $13,954 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $13,088 | Education | In-kind items and services | IMAGE1 PILOT Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $11,443 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind P | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $9,857 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalu | 2025 |
| 2025-12-31 | PFIZER INC. | $9,489 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIP | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $8,330 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $8,000 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $7,286 | Research payment | In-kind items and services | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $5,976 | Education | In-kind items and services | KSlock Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | ABBVIE INC. | $5,587 | Research payment | In-kind items and services | ARMOUR THYROID Drug, THYROID | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and sa | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,270 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $5,183 | Research payment | In-kind items and services | DOCETAXEL Drug, ONCOLOGY | A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resista | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $4,356 | Education | In-kind items and services | VITOM Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $3,612 | Education | In-kind items and services | TELE PACK Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | PFIZER INC. | $3,602 | Research payment | Cash or cash equivalent | ELREXFIO Drug, ONCOLOGY | A PHASE 1B OPENLABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PARTICIPANTS WITH RELAPS | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $3,200 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Immucor, Inc. | $2,885 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-31 | Sequel Med Tech, LLC | $2,400 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Merck Sharp & Dohme LLC | $2,257 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 2, Multicenter, Double-blind, Extension Study to Evaluate the Effects of Sotatercept for the Treatment of Combin | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $2,223 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $2,102 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $2,032 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $1,437 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $1,395 | Education | In-kind items and services | KSlock Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $1,395 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-31 | Stryker Corporation | $1,343 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $1,334 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,275 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | 2025 | |
| 2025-12-31 | ABBVIE INC. | $1,242 | Research payment | In-kind items and services | BOTOX Biological, FACIAL AESTHETICS | A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neu | 2025 |
| 2025-12-31 | Scientia Vascular | $1,200 | Gift (2 payments) | In-kind items and services | ZOOM Device, NEURO | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $960 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $847 | Education | In-kind items and services | n.a. Device, VIDEOIMAGING | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $755 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | Viseon, Inc. | $749 | Debt forgiveness | In-kind items and services | MaxView System - Lateral Set Device, Spinal Surgery | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $746 | Education | In-kind items and services | HOPKINS Device, ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $746 | Education | In-kind items and services | HOPKINS Device, ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $746 | Education | In-kind items and services | HOPKINS Device, ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $737 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $668 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $666 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $653 | Education | In-kind items and services | SilCut Device, D-ENT | 2025 | |
| 2025-12-31 | Siemens Medical Solutions USA, Inc. | $582 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-31 | Grifols Therapeutics LLC | $500 | Research payment | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With 'Acute-On-Chron | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $494 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $494 | Education | In-kind items and services | n.a. Device, A-NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $494 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $494 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $488 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $474 | Education | In-kind items and services | n.a. Device, LAPAROSCOPY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $405 | Education | In-kind items and services | RHINOFORCE Device, ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $394 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | KARL STORZ Endoscopy-America | $354 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Merck Sharp & Dohme LLC | $350 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab MK-3475 plus Chemotherapy vs Placebo plus Chemotherapy for | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $339 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $323 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $288 | Education | In-kind items and services | RHINOFORCE Device, D-ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $249 | Education | In-kind items and services | RHINOFORCE Device, manual lookup | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $232 | Education | In-kind items and services | KSlock Device, MICRO/NOTES/MILITARY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $209 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | Sequel Med Tech, LLC | $146 | Research payment | Cash or cash equivalent | TWIIST Device, AUTOMATED INSULIN DELIVERY DEVICE | Innovative Automated Insulin Delivery System for T2D | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $145 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | Boehringer Ingelheim International GmbH | $133 | Research payment | In-kind items and services | A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with | 2025 | |
| 2025-12-31 | Grifols Therapeutics LLC | $130 | Research payment | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | Effects of Plasma Exchange With Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects With 'Acute-On-Chron | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $114 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $108 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $85 | Education | In-kind items and services | n.a. Device, ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $55 | Education | In-kind items and services | n.a. Device, ENT | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $43 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $43 | Education | In-kind items and services | n.a. Device, NEUROSURGERY | 2025 | |
| 2025-12-31 | KARL STORZ Endoscopy-America | $36 | Education | In-kind items and services | 2025 | ||
| 2025-12-31 | ABBVIE INC. | $24 | Research payment | In-kind items and services | EPKINLY Drug, ONCOLOGY | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffus | 2025 |
| 2025-12-31 | KARL STORZ Endoscopy-America | $1 | Debt forgiveness | In-kind items and services | 2025 | ||
| 2025-12-30 | Medtronic, Inc. | $2,112 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2025 |
| 2025-12-30 | PROGENICS PHARMACEUTICALS, INC. | $1,452 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | 2025 |
| 2025-12-30 | Ipsen Pharma SAS | $390 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-12-29 | Synthes GmbH | $25,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-12-29 | Janssen Research & Development, LLC | $4,158 | Research payment | Cash or cash equivalent | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, | 2025 | |
| 2025-12-29 | Regeneron Pharmaceuticals, Inc. | $2,477 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-29 | Regeneron Pharmaceuticals, Inc. | $2,477 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-29 | Biosense Webster, Inc. | $1,396 | Research payment | Cash or cash equivalent | A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination | 2025 | |
| 2025-12-29 | Biosense Webster, Inc. | $1,000 | Research payment | Cash or cash equivalent | A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | SANOFI PASTEUR INC. | $914 | Research payment | Cash or cash equivalent | Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Ad | 2025 | |
| 2025-12-29 | Biosense Webster, Inc. | $500 | Research payment | Cash or cash equivalent | A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination | 2025 | |
| 2025-12-29 | Biosense Webster, Inc. | $396 | Research payment | Cash or cash equivalent | A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination | 2025 | |
| 2025-12-29 | Incyte Corporation | $390 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis | 2025 | |
| 2025-12-29 | Regeneron Pharmaceuticals, Inc. | $207 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-29 | Regeneron Pharmaceuticals, Inc. | $207 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-29 | Regeneron Pharmaceuticals, Inc. | $207 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-26 | Blue Earth Diagnostics | $5,065 | Research payment | In-kind items and services | Comparison of rhPSMA and fluciclovine in high risk primary disease. Compare the detection of clinically significant pros | 2025 | |
| 2025-12-26 | Janssen Research & Development, LLC | $1,450 | Research payment | Cash or cash equivalent | A Phase 1 First In Human Open Label Dose Escalation Study of JNJ64407564 a Humanized GPRC5D x CD3 DuoBody Antibody in Su | 2025 | |
| 2025-12-25 | Janssen Research & Development, LLC | $14,977 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Tecl | 2025 |
| 2025-12-25 | Biosense Webster, Inc. | $1,584 | Research payment | Cash or cash equivalent | A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination | 2025 | |
| 2025-12-24 | Janssen Research & Development, LLC | $68,056 | Research payment | Cash or cash equivalent | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, | 2025 | |
| 2025-12-24 | Verastem, Inc. | $18,280 | Research payment | Cash or cash equivalent | VS-6766-011 | 2025 | |
| 2025-12-24 | Merck Sharp & Dohme LLC | $9,276 | Research payment | Cash or cash equivalent | CAPVAXIVE Biological, VACCINE | A Test-Negative Case-Control Study to Evaluate the Effectiveness of V116 Against Pneumococcal Pneumonia in Older Adults | 2025 |
| 2025-12-24 | ViiV Healthcare Company | $3,150 | Research payment | Cash or cash equivalent | A PHASE 4, RANDOMIZED, OPEN-LABEL, THREE-ARM STUDY TO EVALUATE IMPLEME | 2025 | |
| 2025-12-24 | Daiichi Sankyo Inc. | $2,717 | Research payment | Cash or cash equivalent | U31402-A-U201 | 2025 | |
| 2025-12-24 | ViiV Healthcare Company | $2,660 | Research payment | Cash or cash equivalent | A PHASE 4, RANDOMIZED, OPEN-LABEL, THREE-ARM STUDY TO EVALUATE IMPLEME | 2025 | |
| 2025-12-24 | ViiV Healthcare Company | $2,150 | Research payment | Cash or cash equivalent | PHASE 1/2 STUDY OF SWITCHING TO FIXED DOSE COMBINATION DOLUTEGRAVIR/RI | 2025 | |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $1,606 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $1,606 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,605 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,580 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,122 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $986 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
| 2025-12-24 | Regeneron Pharmaceuticals, Inc. | $888 | Research payment | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH REL | 2025 |
The latest 200 records of 5,150.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Atlanta, GA, county Fulton County, GA, state Georgia; placed by its city name.
| Measure | Place (city or town) Atlanta, GA | County Fulton County, GA | State Georgia |
|---|---|---|---|
| Population B01003 | 505,268 | 1,076,561 | 10,940,407 |
| Population, 2020 census P1 | 498,715 | 1,066,710 | 10,711,908 |
| Median age B01002 | 34.2 | 36.4 | 37.6 |
| Under 18 B01001 | 16.6% | 20.9% | 23.2% |
| 65 and over B01001 | 12.3% | 12.7% | 15.0% |
| Households B11001 | 236,468 | 462,481 | 4,074,366 |
| Foreign born B05002 | 9.0% | 14.1% | 11.2% |
| Median household income B19013 | $85,652 | $95,292 | $77,353 |
| Median family income B19113 | $118,333 | $130,000 | $93,754 |
| Per capita income B19301 | $65,718 | $63,269 | $40,924 |
| Poverty rate B17001 | 16.9% | 12.3% | 13.4% |
| Unemployment rate B23025 | 5.9% | 5.4% | 5.1% |
| Civilian labor force B23025 | 295,134 | 609,750 | 5,496,061 |
| Mean commute (minutes) B08013 | 26.5 | 27.7 | 28.3 |
| Bachelor's degree or higher B15003 | 59.2% | 58.5% | 34.9% |
| Housing units B25001 | 265,899 | 507,119 | 4,541,835 |
| Owner-occupied B25003 | 46.4% | 54.3% | 65.7% |
| Renters B25003 | 53.6% | 45.7% | 34.3% |
| Median home value B25077 | $439,600 | $458,800 | $303,300 |
| Median gross rent B25064 | $1,711 | $1,732 | $1,393 |
| White, not Hispanic B03002 | 38.1% | 36.8% | 49.1% |
| Black B03002 | 45.4% | 42.1% | 30.7% |
| Hispanic or Latino B03002 | 6.3% | 8.2% | 11.0% |
| Asian B03002 | 5.2% | 7.8% | 4.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 3.3% in Sep 2026 (3.4% a year earlier); per capita personal income $65,111 in 2025, up 26% in five years (+1.6% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Atlanta, GA.
Comments